Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label layperson terms. Show all posts
Showing posts with label layperson terms. Show all posts

Friday, May 29, 2026

Can kinase trafficking to mitochondria unlock new targets in ischemic stroke?

 Ask your competent? doctor to translate this word salad to layperson terms. Will something from here get survivors to 100% recovery?

Can kinase trafficking to mitochondria unlock new targets in ischemic stroke?

Stroke is a major cause of death and permanent disability, which is described by abrupt loss of neuronal energy, oxidative injury, inflammation, and apoptosis, primarily mediated by mitochondrial dysfunction. Mitochondria are key regulators of stress responses, apoptosis, redox homeostasis, immune signaling and known as central signaling hubs, integrating pathways from multiple cellular compartments to maintain homeostasis. Among the major regulatory elements are protein kinase enzymes that modulate cell signaling by phosphorylating substrates. Several kinases, including members of the Akt, PKA, PKC, GSK-3β, PINK1, and MAPK families, dynamically translocate to mitochondria under physiological and pathological conditions. Once localized, they influence mitochondrial dynamics, bioenergetics, reactive oxygen species (ROS) production, and programmed cell death. Dysregulation of these functions has been implicated in impaired mitophagy, aberrant calcium signaling, and processes associated with the pathogenesis of various neurological disorders, particularly in those with acute brain injuries, such as acute ischemic stroke (AIS). Especially, mitochondrial kinase oxidative stress hallmarks of neuronal injury. In this review, we examine the role of mitochondrial-associated kinases in AIS, explore mechanisms of their translocation, downstream signaling effects, and their promise as druggable targets highlighting the importance of spatial dynamics of kinases and the need for precision therapies. Understanding these mechanisms may open new avenues for therapeutic intervention in neurological diseases with a focus on acute brain injury, by targeting mitochondrial signaling networks.

Saturday, December 2, 2023

Spatial mapping of posture-dependent resistance to passive displacement of the hypertonic arm post-stroke

In layperson terms does anything here get survivors recovered?

Spatial mapping of posture-dependent resistance to passive displacement of the hypertonic arm post-stroke

Abstract

Background

Muscles in the post-stroke arm commonly demonstrate abnormal reflexes that result in increased position- and velocity-dependent resistance to movement. We sought to develop a reliable way to quantify mechanical consequences of abnormal neuromuscular mechanisms throughout the reachable workspace in the hemiparetic arm post-stroke.

Methods

Survivors of hemiparetic stroke (HS) and neurologically intact (NI) control subjects were instructed to relax as a robotic device repositioned the hand of their hemiparetic arm between several testing locations that sampled the arm's passive range of motion. During transitions, the robot induced motions at either the shoulder or elbow joint at three speeds: very slow (6°/s), medium (30°/s), and fast (90°/s). The robot held the hand at the testing location for at least 20 s after each transition. We recorded and analyzed hand force and electromyographic activations from selected muscles spanning the shoulder and elbow joints during and after transitions.

Results

Hand forces and electromyographic activations were invariantly small at all speeds and all sample times in NI control subjects but varied systematically by transport speed during and shortly after movement in the HS subjects. Velocity-dependent resistance to stretch diminished within 2 s after movement ceased in the hemiparetic arms. Hand forces and EMGs changed very little from 2 s after the movement ended onward, exhibiting dependence on limb posture but no systematic dependence on movement speed or direction. Although each HS subject displayed a unique field of hand forces and EMG responses across the workspace after movement ceased, the magnitude of steady-state hand forces was generally greater near the outer boundaries of the workspace than in the center of the workspace for the HS group but not the NI group.

Conclusions

In the HS group, electromyographic activations exhibited abnormalities consistent with stroke-related decreases in the stretch reflex thresholds. These observations were consistent across repeated testing days. We expect that the approach described here will enable future studies to elucidate stroke's impact on the interaction between the neural mechanisms mediating control of upper extremity posture and movement during goal-directed actions such as reaching and pointing with the arm and hand.

Introduction

Muscles in the post-stroke arm commonly demonstrate abnormal reflexes that result in increased position- and velocity-dependent resistance to movement (i.e. spastic hypertonus: [21, 25]. Spastic hypertonia is understood to reflect systematic reductions in stretch reflex thresholds [16, 24], decreased range of regulation of these stretch reflex thresholds [23, 47], as well as altered non-reflex phenomena such as abnormalities in the intrinsic mechanical properties of spastic muscles and altered viscoelastic properties of passive tissues [28, 43, 49]. Importantly, systematic reduction in stretch reflex threshold could lead to significant increase in stretch reflex excitability [17] and agonist/antagonist coactivation in some regions of the workspace [22, 30], which could lead to complex, posture-dependent and potentially time-varying joint impedances in the hemiparetic arm. Because the feedforward control of goal-directed movements relies on accurate predictions of limb impedance [38], spatial and temporal complexity of joint impedance may be a significant contributor to impairment of movement coordination post-stroke [20, 40, 48]. Although a velocity-dependent increase in muscle tone (spasticity is frequently assessed clinically and has been quantified in single joints such as the elbow and wrist [15, 23, 26, 44], quantitative assessments of multi-joint control deficits have been rare (see [30, 36]) and sometimes rely on techniques such as kinematic and/or inverse dynamics analyses, which can be insensitive to the presence and effects of abnormal muscle coactivations (e.g., [18, 33]).

The goal of this study was to develop a reliable approach for measuring the mechanical consequences of abnormal neuromuscular mechanisms as a function of hand location in the reachable workspace in the hemiparetic arm post-stroke. We are motivated in this work by a growing body of experimental evidence supporting the idea that the neural mechanisms contributing to the control of limb posture and movement can be differentially compromised by stroke [19, 27, 40], see also [8, 37, 48] and by other neuromotor disorders (cf. [10, 11]), and by the belief that greater understanding of the mechanisms contributing to sensorimotor deficits will eventually lead to improved efficacy of therapeutic interventions [13]. Our work builds on prior studies that examined transient mechanical and electromyographic responses to passive displacements of the wrist or elbow to quantitatively assess post-stroke spasticity (cf. [15, 23, 26, 44, 47]) and spastic dystonia [46]. In one example, Schmit and colleagues used a motorized device to passively flex and extend the elbow of hemiparetic stroke survivors over a range of speeds ranging from slow (6º/s) to fast (90º/s) [44]. Their goal was to assess the reliability of three different biomechanical correlates of spasticity, which they isolated from other aspects of spastic hypertonia associated with dystonia, contracture, and increased joint stiffness. They did so by subtracting the torque response to the slowest displacement from responses to faster displacements, leaving only reflex torque. This approach is effective because the stiffness of the passive tissues about the elbow joint are largely velocity insensitive [9]. Of the three biomechanical measures considered—peak torque, peak joint stiffness, and onset angle of reflex torque responses—peak torque values measured during displacements at 90°/s were most reliable on repeated measures in a single testing session (> 80% reliability), and most highly correlated with clinical assessments of spasticity (Ashworth Scale). In another example, Mirbhageri and colleagues [29] used system identification techniques to quantify the contributions of reflex and intrinsic (i.e., non-reflex) stiffness to total elbow stiffness at several different elbow angles in the paretic and nonparetic arm of chronic hemiparetic stroke survivors. Each position was examined under passive conditions in the range of full elbow flexion to full elbow extension. They reported that intrinsic and reflex stiffness both contributed strongly to net joint torque, that the effects were significantly larger in the paretic than in the non-paretic elbow muscles, and that these differences increased with the increasing joint angle indicating position dependence. Although these prior studies suggest that manifestations of spasticity and hypertonia may vary in complex ways across the reachable workspace after stroke, a more comprehensive approach to quantifying mechanical expressions of spasticity and hypertonia across the workspace has yet to be described.

We designed a set of experiments using a two-joint, planar robot to measure the dynamic and quasistatic mechanical and electromyographic responses to controlled displacements of the upper extremity at several locations in the arm’s workspace. Subjects were instructed to relax as the robot moved their hand sequentially between target locations spanning the reachable workspace at speeds ranging from very slow to fast. Trajectories were selected such that movements were largely limited to either the shoulder or elbow joint, but not both. The robot stabilized the hand at the target for at least 20 s following the end of each movement. We analyzed the time series of horizontal planar hand forces and electromyographic (EMG) activations for selected arm muscles to determine the duration of phasic, velocity-dependent resistance to stretch, to characterize the spatial topography of tonic, position-dependent hand forces throughout the workspace, and to characterize the muscle activations that give rise to these postural bias forces. The resulting data demonstrate that the robotic assessment of posture-dependent bias forces was repeatable across days, that the phasic component of these stroke-related forces lasted no more than 2 s after the end of limb re-positioning, and that these bias forces were partly neuromuscular in origin (not merely due to passive tissue resistance to stretch) such that elevated “resting” EMG activations exhibited posture-dependence in some muscles, but posture-invariance in others. We expect that quantitative evaluation of posture-dependent bias forces may facilitate future assessments of stroke's impact on the interaction between the control of upper extremity posture and movement.

More at link.

Friday, March 25, 2022

Some antihypertensives may reduce risk for cognitive decline

Lots of words but zero understanding since it doesn't tell in layperson terms which ones are good for that.

Some antihypertensives may reduce risk for cognitive decline

 

Certain antihypertensive medications may help prevent cognitive decline, according to results of a cohort study published in JAMA Network Open.

“Although use of antihypertensive medications that stimulate (angiotensin II receptor type 1 blockers, dihydropyridine calcium channel blockers and thiazide diuretics) vs. inhibit (angiotensin-converting enzyme [ACE] inhibitors, beta-blockers and nondihydropyridine calcium channel blockers) type 2 and 4 angiotensin II receptors has been associated with lower risk of dementia, their association with cognitive outcomes in hypertension trials, with BP levels in the range of current guidelines, has not been evaluated,” Zachary A. Marcum, PharmD, PhD, associate professor in the department of pharmacy at the University of Washington, and colleagues wrote. “Examining this question in the context of contemporary BP levels can provide clinically relevant insights into antihypertensive associations with adjudicated cognitive outcomes, independent of their BP-lowering effects.

doctor checking blood pressure
Source: Adobe Stock

“Thus, we assessed the association of prevalent use of antihypertensive regimens that exclusively contain medications that stimulate vs. inhibit type 2 and 4 angiotensin II receptors on MCI or probable dementia in the Systolic Blood Pressure Intervention Trial (SPRINT),” they added.

Marcum and colleagues conducted the secondary analysis of individuals aged 50 years or older with hypertension and increased cardiovascular risk but no history of diabetes, stroke or dementia who participated in the randomized SPRINT Trial. As the exposure, they examined prevalent use of angiotensin II receptor type 2 and 4-stimulating or -inhibiting antihypertensive medication regimens at 6 months. A composite of adjudicated amnestic mild cognitive impairment or probable dementia served as the primary outcome.

A total of 8,685 participants prevalently used antihypertensive medication regimens at 6 months (mean age, 67.7 years; 64.3% men), of whom 2,644 (30.4%) used exclusively stimulating, 1,536 (17.7%) inhibiting and 4,505 (51.9%) mixed antihypertensive medication regimes.

Across a median of 4.8 years of follow-up, Marcum and colleagues noted 45 vs. 59 cases per 1,000 person-years of amnestic mild cognitive impairment or probable dementia among prevalent users of regimens featuring exclusively stimulating vs. inhibiting antihypertensive medications (HR = 0.76; 95% CI, 0.66-0.87). When they compared stimulating-only with inhibiting-only users, they found amnestic mild cognitive impairment rates of 40 vs. 54 cases per 1,000 person-years (HR = 0.74; 95% CI, 0.64-0.87) and probable dementia rates of eight vs. 10 cases per 1,000 person-years (HR = 0.8; 95% CI, 0.57-1.14). Further, they noted residual confounding, according to results of negative control outcome analyses.

“If these results are replicated in randomized clinical trials, certain antihypertensives could be prioritized to prevent the development of cognitive decline,” Marcum and colleagues wrote.

Monday, June 21, 2021

Structural Connectivity Remote From Lesions Correlates With Somatosensory Outcome Poststroke

 In layperson terms what does this mean and how do survivors use this to recover?

Structural Connectivity Remote From Lesions Correlates With Somatosensory Outcome Poststroke

Originally publishedhttps://doi.org/10.1161/STROKEAHA.120.031520Stroke. ;0:STROKEAHA.120.031520

Background and Purpose:

Changes in connectivity of white matter fibers remote to a stroke lesion, suggestive of structural connectional diaschisis, may impact on clinical impairment and recovery after stroke. However, until recently, we have not had tract-specific techniques to map changes in white matter tracts in vivo in humans to enable investigation of potential mechanisms and clinical impact of such remote changes. Our aim was to identify and quantify white matter tracts that are affected remote from a stroke lesion and to investigate the associations between reductions in tract-specific connectivity and impaired touch discrimination function after stroke.

Methods:

We applied fixel-based analysis to diffusion magnetic resonance imaging data from 37 patients with stroke (right lesion =16; left lesion =21) and 26 age-matched healthy adults. Three quantitative metrics were compared between groups: fiber density; fiber-bundle cross-section; and a combined measure of both (fiber-bundle cross-section) that reflects axonal structural connectivity.

Results:

Compared with healthy adults, patients with stroke showed significant common fiber-bundle cross-section and fiber density reductions in 4 regions remote from focal lesions that play roles in somatosensory and spatial information processing. Structural connectivity along the somatosensory fibers of the lesioned hemisphere was correlated with contralesional hand touch function. Touch function of the ipsilesional hand was associated with connectivity of the superior longitudinal fasciculus, and, for the right-lesion group, the corpus callosum.

Conclusions:

Remote tract-specific reductions in axonal connectivity indicated by diffusion imaging measures are observed in the somatosensory network after stroke. These remote white matter connectivity reductions, indicative of structural connectional diaschisis, are associated with touch impairment in patients with stroke.

 

Tuesday, January 8, 2019

Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists

You'll have to ask your doctor to decipher this into layperson terms and where to get these cocktails, Yes, these are in mice but unless YOU light a fire under your doctor nothing will be done for when you need this.  

Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists



Open AccessPublished: January 2, 2019DOI:https://doi.org/10.1016/j.celrep.2018.12.021

Highlights

  • •
    Screen for antagonist of PrPC binding to Aβo identifies polymeric antibiotic degradant
  • •
    Class of polymeric nM-potent PrPC antagonists rescue Aβo-induced phenotypes in vitro
  • •
    PrPC antagonists also clear neuroblastoma cells of PrPSc replication
  • •
    Oral PrPC antagonist rescues transgenic AD mouse synapse loss and memory deficits

Summary

Cellular prion protein (PrPC) binds the scrapie conformation of PrP (PrPSc) and oligomeric β-amyloid peptide (Aβo) to mediate transmissible spongiform encephalopathy (TSE) and Alzheimer’s disease (AD), respectively. We conducted cellular and biochemical screens for compounds blocking PrPC interaction with Aβo. A polymeric degradant of an antibiotic targets Aβo binding sites on PrPC with low nanomolar affinity and prevents Aβo-induced pathophysiology. We then identified a range of negatively charged polymers with specific PrPC affinity in the low to sub-nanomolar range, from both biological (melanin) and synthetic (poly [4-styrenesulfonic acid-co-maleic acid], PSCMA) origin. Association of PSCMA with PrPC prevents Aβo/PrPC-hydrogel formation, blocks Aβo binding to neurons, and abrogates PrPSc production by ScN2a cells. We show that oral PSCMA yields effective brain concentrations and rescues APPswe/PS1ΔE9 transgenic mice from AD-related synapse loss and memory deficits. Thus, an orally active PrPC-directed polymeric agent provides a potential therapeutic approach to address neurodegeneration in AD and TSE.

Graphical Abstract

Keywords

Introduction
Extensive evidence points to the oligomeric form of β-amyloid peptide (Aβo) as the trigger to initiate Alzheimer’s pathology (
,
,
,
), but clinical measures to reduce brain Aβ burden have been therapeutically ineffective (
), inspiring exploration for alternate strategies. Discovery that cellular prion protein (PrPC) acts as a high-affinity neuronal receptor required for toxic Aβo signaling (
,
,
,
) has led to the identification of several effectors downstream of Aβo/PrPC interaction, such as mGluR5 (
,
,
,
), Fyn kinase (
,
,
), and Pyk2 kinase (
,
), that can be targeted pharmacologically to rescue the murine brain from AD model pathology. Abrogation of Aβo/PrPC interaction itself in vivo, genetically (
,
) or with antibodies directed against the Aβo-binding domains on PrPC (
,
,
), also reverses synaptic degeneration and restores behavioral performance to impaired AD model mice, even as Aβ load is unaltered. These data indicate the possibility of disease intervention independently of Aβo clearance and identify Aβo/PrPC interaction as an opportune nexus for pharmacological intervention after Aβ accumulation occurs.
Cell-surface PrP is a conformationally diverse protein, originally identified as effecting transmissible spongiform encephalopathy (TSE) via a template-induced proteinase K-resistant form (
). Conversion of PrPC to infectious scrapie (PrPSc) refolds the C-terminal segment, while the toxic action of PrPSc also requires natively unfolded N terminus (
). Recently, we showed that cell surface PrPC engages in phase state changes between soluble, liquid, and hydrogel (
). The mobile liquid state exists at endogenous PrPC levels present in lipid rafts. The relatively immobile hydrogel phase is induced upon association with multivalent Aβo. Lateral mobility of PrPC in the membrane is restricted upon Aβo association, and mGluR5 is trapped in the hydrogel. Upon Aβo association, the unstructured N-terminal PrP domain adopts an α-helical structure, which coincides with the engagement of mGluR5 and consequent synaptotoxic signaling though Fyn and Pyk2 kinases.
Transgenic APPswe/PS1ΔE9 mice (APP/PS1) expressing the human mutant amyloid precursor protein (APP) and presenilin 1 (PS1) proteins that cause early onset AD exhibit certain pathological characteristics (
). Age-dependent accumulation of Aβo and abundant amyloid plaques, synaptic degeneration, dendritic spine loss, Fyn dysregulation, microglial and astrocytic activation, and multiple memory deficits are among APP/PS1 histopathologies and functional deficits (
). Because later-stage AD symptoms such as tau tangle accumulation and cell loss are not evident in APP/PS1 and similar strains (
), these models may reflect an early AD stage, at which Aβo-directed intervention might have the greatest impact.
Here, we describe competitive antagonists of Aβo/PrPC interaction. These compounds target PrPC Aβo-binding domains, thereby preventing Aβo association with PrPC, Aβo action in vitro, and APP/PS1 phenotypes in vivo. Additionally, these N terminus-directed ligands potently inhibit PrPSc propagation in culture, suggesting efficacy across PrPC-mediated neurodegenerative diseases.

Results

 Ceftazidime Degradation Yields a Potent Polymeric Aβo/PrPC Inhibitor Termed Compound “Z”

To search for inhibitors of Aβo/PrPC interaction we engaged in a high throughput cell-based screen using stably PrPC-transfected CV-1 cells. Aβo prepared from biotinylated synthetic Aβ42 peptide associates with these cells in a PrPC-dependent fashion that can be blocked by an antibody (6D11) directed against the Aβo-binding domain at PrPC 90-111 (Figures 1A and 1B). From a screen of 2,560 known drug and 10,130 diverse small molecules, the cephalosporin antibiotic cefixime sample was found to be highly inhibitory. Upon attempted validation, neither fresh cefixime nor a range of cephalosporins was found to possess inhibitory activity, suggesting an impurity or degradation product of cefixime was responsible (compound “X”). To investigate this possibility, five different cephalosporins were allowed to stand in DMSO at 23C for 6 days before re-testing. In addition to cefixime, ceftazidime exhibited activity resulting from prolonged incubation (compound “Z”), while other cephalosporins (cefdinir, cefotaxime, and ceftriaxone) exhibited zero activity either freshly diluted or after 6 days in DMSO (Figure 1C). Inhibitory activity developed progressively from ceftazidime incubated in sodium carbonate at 23°C over 9 days (Figure S1).

Figure thumbnail gr1
Figure 1Cefixime or Ceftazidime Degradation Produces HMW Inhibitor of Aβo/PrPC Interaction

Wednesday, December 14, 2016

Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke

For your doctor to explain because our fucking failures of stroke associations do not translate stroke research into layperson understandable terms.
 https://www.mdlinx.com/internal-medicine/medical-news-article/2015/12/09/alteplase-cerebral-hemorrhage-factor-v-prothrombin/6428892/?
Stroke, 12/09/2015
The authors compared the fibrinolytic activity of tenecteplase and alteplase in patients with acute ischemic stroke, and explored the association between hypofibrinogenaemia and intracerebral hemorrhage. In patients with acute ischemic stroke, alteplase 0.9 mg/kg caused significant disruption of the fibrinolytic system, whereas tenecteplase 0.25 mg/kg did not, consistent with the trend toward lower intracerebral hemorrhage incidence with tenecteplase in the ATTEST study.

Methods

  • Venous blood samples from a subgroup of participants in the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) study were obtained at pretreatment, 3 to 12 hours, and 24±3 hours post-intravenous thrombolysis for analyses of plasminogen, plasminogen activator inhibitor-1, d-dimer, factor V, fibrinogen, and fibrin(ogen) degradation products, in addition to routine coagulation assays.
  • Related sample Wilcoxon signed-rank tests were used to test the within-group changes, and independent Mann-Whitney tests for between-group differences.

Results

  • Thirty patients were included (alteplase=14 and tenecteplase=16) with similar baseline demographics.
  • Compared with baseline, alteplase caused significant hypofibrinogenaemia (P=0.002), prolonged prothrombin time (P=0.011), hypoplasminogenaemia (P=0.001), and lower factor V (P=0.002) at 3 to 12 hours after administration with persistent hypofibrinogenaemia at 24 hours (P=0.011), whereas only minor hypoplasminogenaemia (P=0.029) was seen in the tenecteplase group.
  • Tenecteplase consumed less plasminogen (P<0.001) and fibrinogen (P=0.002) compared with alteplase.
Go to PubMed Go to Abstract Print Article Summary Cat 2 CME Report